|
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event
reported): February 14, 2020
ClearPoint
Neuro, Inc.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
DELAWARE
|
001-34822
|
58-2394628
|
|
(State or other jurisdiction
of incorporation)
|
(Commission
File Number)
|
(I.R.S. Employer
Identification Number)
|
5 Musick
Irvine, CA 92618
(Address of principal executive offices, zip code)
(949) 900-6833
(Registrant’s telephone number, including
area code)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
|
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
Title
of each class
|
Trading
Symbol(s)
|
Name
of each exchange on which registered
|
|
Common Stock, $0.01 par value per share
|
CLPT
|
Nasdaq Capital Market
|
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by
check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
|
|
Item 7.01.
|
Regulation FD Disclosure.
|
On February 14, 2020, ClearPoint
Neuro, Inc. (formerly MRI Interventions, Inc.) (the “Company”) issued a press release announcing its revenue outlook
for 2020. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
On February 14, 2020, the Company
also posted an updated investor presentation to its website at http://ir.stockpr.com/mriinterventions/investor-presentations. A
copy of the investor presentation is furnished as Exhibit 99.2 to this Current Report on Form 8-K. The Company may use the investor
presentation from time to time in conversations with analysts, investors and others.
The information in Item 7.01
of this Current Report on Form 8-K, as well as Exhibits 99.1 and 99.2 attached hereto, shall not be deemed “filed”
for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall
they be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except
as shall be expressly set forth by specific reference in such a filing.
|
|
Item 9.01.
|
Financial Statements and Exhibits.
|
(d) Exhibits.
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
|
|
|
|
Date: February 14, 2020
|
MRI INTERVENTIONS, INC.
|
|
|
|
|
|
|
By:
|
/s/ Harold A. Hurwitz
|
|
|
|
Harold A. Hurwitz
|
|
|
|
Chief Financial Officer
|
| 
